Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver

Clinica Chimica Acta

Volumn 424, Issue , 2013, Pages 99-103

  Yamada, Hiroya ^a   Suzuki, Koji ^b   Ichino, Naohiro ^b   Ando, Yoshitaka ^b   Sawada, Akira ^b   Osakabe, Keisuke ^b   Sugimoto, Keiko ^b   Ohashi, Koji ^b   Teradaira, Ryouji ^b   Inoue, Takashi ^b   Hamajima, Nobuyuki ^c   Hashimoto, Shuji ^a  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b FUJITA HEALTH UNIVERSITY   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Circulating microRNA; Cross sectional study; Epidemiology; General people; Liver steatosis; NAFLD

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; FATTY ACID; GAMMA GLUTAMYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MICRORNA; MICRORNA 122; MICRORNA 21; MICRORNA 34A; MICRORNA 451; NITROGEN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UREA;

AGED; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ECHOGRAPHY; FEMALE; HOMEOSTASIS; HUMAN; LIVER; MAJOR CLINICAL STUDY; MALE; MEDICAL EXAMINATION; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM;

CIRCULATING MICRORNA; CROSS-SECTIONAL STUDY; EPIDEMIOLOGY; GENERAL PEOPLE; LIVER STEATOSIS; NAFLD;

AGED; ASYMPTOMATIC DISEASES; BIOLOGICAL MARKERS; CHOLESTEROL; CROSS-SECTIONAL STUDIES; FATTY ACIDS; FATTY LIVER; FEMALE; HUMANS; JAPAN; MALE; MICRORNAS; MIDDLE AGED; REAL-TIME POLYMERASE CHAIN REACTION; SEVERITY OF ILLNESS INDEX;

EID: 84879448114     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2013.05.021     Document Type: Article

References (39)

1. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
2. Weber J.A., Baxter D.H., Zhang S., et al. The microRNA spectrum in 12 body fluids. Clin Chem 2010, 56:1733-1741.
3. Cortez M.A., Bueso-Ramos C., Ferdin J., et al. MicroRNAs in body fluids-the mix of hormones and biomarkers. Nat Rev Clin Oncol 2011, 8:467-477.
4. Park N.J., Zhou H., Elashoff D., et al. Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Clin Cancer Res 2009, 15:5473-5477.
5. Mitchell P.S., Parkin R.K., Kroh E.M., et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008, 105:10513-10518.
6. McDonald J.S., Milosevic D., Reddi H.V., Grebe S.K., Algeciras-Schimnich A. Analysis of circulating microRNA: preanalytical and analytical challenges. Clin Chem 2011, 57:833-840.
7. Gilad S., Meiri E., Yogev Y., et al. Serum microRNAs are promising novel biomarkers. PLoS One 2008, 3:e3148.
8. Kong Y.W., Ferland-McCollough D., Jackson T.J., Bushell M. MicroRNAs in cancer management. Lancet Oncol 2012, 13:e249-e258.
9. Esteller M. Non-coding RNAs in human disease. Nat Rev Genet 2011, 12:861-874.
10. Wang X.W., Heegaard N.H., Orum H. MicroRNAs in liver disease. Gastroenterology 2012, 142:1431-1443.
11. Divakaran V., Mann D.L. The emerging role of microRNAs in cardiac remodeling and heart failure. Circ Res 2008, 103:1072-1083.
12. Chandrasekaran K., Karolina D.S., Sepramaniam S., et al. Role of microRNAs in kidney homeostasis and disease. Kidney Int 2012, 81:617-627.
13. Carissimi C., Fulci V., Macino G. MicroRNAs: novel regulators of immunity. Autoimmun Rev 2009, 8:520-524.
14. Tiniakos D.G., Vos M.B., Brunt E.M. Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu Rev Pathol 2010, 5:145-171.
15. Matteoni C.A., Younossi Z.M., Gramlich T., et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999, 116:1413-1419.
16. Moscatiello S., Di Luzio R., Sasdelli A.S., Marchesini G. Managing the combination of nonalcoholic fatty liver disease and metabolic syndrome. Expert Opin Pharmacother 2011, 12:2657-2672.
17. Pacifico L., Nobili V., Anania C., Verdecchia P., Chiesa C. Pediatric nonalcoholic fatty liver disease, metabolic syndrome and cardiovascular risk. World J Gastroenterol 2011, 17:3082-3091.
18. Cheung O., Puri P., Eicken C., et al. Nonalcoholic steatohepatitis is associated with altered hepatic microRNA expression. Hepatology 2008, 48:1810-1820.
19. Li S., Chen X., Zhang H., et al. Differential expression of microRNAs in mouse liver under aberrant energy metabolic status. J Lipid Res 2009, 50:1756-1765.
20. Alisi A., Da Sacco L., Bruscalupi G., et al. Mirnome analysis reveals novel molecular determinants in the pathogenesis of diet-induced nonalcoholic fatty liver disease. Lab Invest 2011, 91:283-293.
21. Armstrong M.J., Houlihan D.D., Bentham L., et al. Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort. J Hepatol 2012, 56:234-240.
22. Scaglioni F., Ciccia S., Marino M., Bedogni G., Bellentani S. ASH and NASH. Dig Dis 2011, 29:202-210.
23. Strauss S., Gavish E., Gottlieb P., Katsnelson L. Interobserver and intraobserver variability in the sonographic assessment of fatty liver. AJR Am J Roentgenol 2007, 189:320-323.
24. Kroh E.M., Parkin R.K., Mitchell P.S., Tewari M. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods 2010, 50:298-301.
25. Yu S., Liu Y., Wang J., et al. Circulating microRNA profiles as potential biomarkers for diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab 2012, 97:2084-2092.
26. Orom U.A., Nielsen F.C., Lund A.H. MicroRNA-10a binds the 5'UTR of ribosomal protein mRNAs and enhances their translation. Mol Cell 2008, 30:460-471.
27. Esau C., Davis S., Murray S.F., et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 2006, 3:87-98.
28. Elmen J., Lindow M., Schutz S., et al. LNA-mediated microRNA silencing in non-human primates. Nature 2008, 452:896-899.
29. Cermelli S., Ruggieri A., Marrero J.A., Ioannou G.N., Beretta L. Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS One 2011, 6:e23937.
30. Wang K., Zhang S., Marzolf B., et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci U S A 2009, 106:4402-4407.
31. Xu J., Wu C., Che X., et al. Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog 2011, 50:136-142.
32. Starkey Lewis P.J., Dear J., Platt V., et al. Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology 2011, 54:1767-1776.
33. Rolo A.P., Teodoro J.S., Palmeira C.M. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic Biol Med 2012, 52:59-69.
34. Panasiuk A., Dzieciol J., Panasiuk B., Prokopowicz D. Expression of p53, Bax and Bcl-2 proteins in hepatocytes in non-alcoholic fatty liver disease. World J Gastroenterol 2006, 12:6198-6202.
35. Farrell G.C., Larter C.Z., Hou J.Y., et al. Apoptosis in experimental NASH is associated with p53 activation and TRAIL receptor expression. J Gastroenterol Hepatol 2009, 24:443-452.
36. Hermeking H. The miR-34 family in cancer and apoptosis. Cell Death Differ 2010, 17:193-199.
37. Castro R.E., Ferreira D.M., Afonso M.B., et al. miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease. J Hepatol 2013, 58:119-125.
38. Pogribny I.P., Starlard-Davenport A., Tryndyak V.P., et al. Difference in expression of hepatic microRNAs miR-29c, miR-34a, miR-155, and miR-200b is associated with strain-specific susceptibility to dietary nonalcoholic steatohepatitis in mice. Lab Invest 2010, 90:1437-1446.
39. Fu T., Choi S.E., Kim D.H., et al. Aberrantly elevated microRNA-34a in obesity attenuates hepatic responses to FGF19 by targeting a membrane coreceptor β-Klotho. Proc Natl Acad Sci U S A 2012, 109:16137-16142.